Caricamento...
Association of Age and Sex with Mortality Following Adjuvant Therapy for Renal Cancer
BACKGROUND: Adjuvant sunitinib has shown no overall survival (OS) benefit, uncertain disease-free survival (DFS) benefit, and increased toxicity versus placebo in phase III trials of resected high-risk renal cell cancer. To identify patients that may derive benefit or harm from adjuvant therapy, we...
Salvato in:
| Pubblicato in: | Cancer |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6486432/ https://ncbi.nlm.nih.gov/pubmed/30620389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31955 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|